期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

慢性丙型肝炎治疗：更多的机遇，更多的挑战 被引量：5

Treatment for chronic hepatitis C, more opportunity, more challenge
原文传递
导出
摘要 自从聚乙二醇干扰素（PEG—IFN）α联合利巴韦林（RBV）应用于慢性丙型肝炎的治疗，并且基因2型或基因3型感染者可获得50％的持续病毒学应答（SVR）以来，PEG—IFN α联合RBV已经成为慢性丙型肝炎的标准治疗方案^[1-2]。丙型肝炎也被认为是一个可以“治愈的疾病”，其标准是治疗结束时及随访24周后患者外周血HCVRNA低于敏感检测方法的检测水平（50IU／ml或更低），
作者 魏来
机构地区 北京大学人民医院北京大学肝病研究所
出处 《中华肝脏病杂志》 CAS CSCD 北大核心 2009年第7期481-483,共3页 Chinese Journal of Hepatology
关键词 肝炎 丙型 慢性 治疗 Hepatitis C, chronic Therapy
分类号 R686 [医药卫生—骨科学]
  • 相关文献

参考文献21

  • 1Ghany MG,Strader DB,Thomas DL,et al.Diagnosis,management,and treatment of hepatitis C:an update.Hepatology,2009,49:1335-1374.
  • 2Asian Pacific Association for the Study of the Liver (APASL) Hepatitis Working Party.McCaughan GW,Omata M,Amarapurkar D,et al.Asian Pacific Association for the Study of the Liver consensus statements on the diagnosis,management and treatment of hepatitis C virus infection.J Gastroenterol Hepatol,2007,22:615-633.
  • 3Gordon SC.Treatment of viral hepatitis-2001.Ann Med,2001,33:385-390.
  • 4Pawlotsky JM.Trenting hepatitis C in "diffienlt-to-treat" patients.N Engl J Med,2004,351:422-423.
  • 5Fried MW,Jeusen DM,Rodriguez-Torres M,et al.Improved outcomes in patients with hepatitis C with difficult-to-treat characteristics:randomized study of higher doses of peginterferon alpha-2a and ribavirin.Hepatology,2008,48:1033-1043.
  • 6Alberti A.What are the comorbidities influencing the management of patients and the response to therapy in chronic hepatitis C? Liver Int,2009,29 (Suppl 1):15-18.
  • 7Faruik H,Mihm U,Zeuzem S.Optimal therapy in genotype 1 patients.Liver lnt,2009,29 (Suppl 1):23-30.
  • 8Poynard T,Colombo M,Bruix J,et al.Peginterferon alfa-2b and ribavirin:effective in patients with hepatitis C who failed interferon alfa/ribavirin therapy.Crastroenterology,2009,136:1618-1628.
  • 9Jeusen DM,Marcellin P,Freilich B,et al.Re-treatment of patients with chronic hepatitis C who do not respond to pegintefferonaipha2b:a randomized trial.Ann Intern Med,2009,150:528-540.
  • 10Berg T,von Wagner M,Nasser S,et al.Extended treatment duration for hepatitis C virus type 1:comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirin.Gastroenterology,2006,130:1086-1097.

同被引文献53

  • 1丙型肝炎防治指南[J].临床肝胆病杂志,2004,20(4):197-203. 被引量：735
  • 2徐道振,谢尧,陆志檬,骆抗先,贾继东,王宇明,赵桂珍,张树林,张大志.聚乙二醇干扰素α-2a与干扰素α-2a治疗慢性丙型肝炎疗效、安全性的评估[J].中华传染病杂志,2004,22(4):221-224. 被引量：37
  • 3Di Marco V,Capra M,Gagliardotto F,et al.Liver disease in chelated transfusion-dependent thalassemics:the role of iron overload and chronic hepatitis C.Haematotogica,2008,93:1243-1246.
  • 4Tanaka H,Fujita N,Sugimoto R,et al.Hepatic oxidative DNA damage is associated with increased risk for hepatocellular carcinoma in chronic hepatitis C.Br J Cancer,2008,98:580-586.
  • 5Nahon P,Sutton A,Rufat P,et al.Liver iron,HFE gene mutations,and hepatocellular carcinoma occurrence in patients with cirrhosis.Gastroenterology,2008,134:102-110.
  • 6Trinder D,Ayonrinde OT,Olynyk JK.HCV,iron,and oxidative stress:the new choreography of hepcidin.Gastroenterology,2008,134:348-351.
  • 7Valenti L,Pulixi EA,Arosio P,et al.Relative contribution of iron genes,dysmetabolism and hepatitis C virus(HCV)in the pathogenesis of altered iron regulation in HCV chronic hepatitis.Haematologica,2007,92:1037-1042.
  • 8Collins JF,Wessling-Resnick M,Knutson MD.Hepcidin regulation of iron transport.J Nutr,2008,138:2284-2288.
  • 9De Domenico I,Ward DM,Langelier C,et al.The molecular mechanism of hepcidin-mediated ferroportin down-regulation.Mol Biol Cell,2007,18:2569-2578.
  • 10Kijima H,Sawada T,Tomosugi N,et al.Expression of hepcidin mRNA is uniformly suppressed in hepatocellular carcinoma.BMC Caneer,2008,8:167.

引证文献5

二级引证文献34

中华肝脏病杂志
2009年 第7期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部